CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Current Oncology Reports
L SpringA Bardia

Abstract

To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research. Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+ MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Key questions in the field include whether all patients with HR+ MBC should receive a CDK 4/6 inhibitor up front versus later line, impact on overall survival, role of continued CDK 4/6 blockade, mechanism of clinical resistance, and treatment sequencing. The development of CDK 4/6 inhibitors has changed the therapeutic management of HR+ MBC. Additional research is needed to determine optimal treatment sequencing, understand mechanisms governing resistance, and develop novel therapeutic strategies to circumvent or overcome clinical resistance and further improve the outcomes of patients with MBC.

References

Jan 1, 1994·Advances in Cancer Research·J Y WangP J Welch
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·E A MusgroveR L Sutherland
Dec 6, 1996·Science·C J Sherr
Oct 15, 1998·Nature Medicine·P NurseL Hartwell
Apr 2, 2005·Journal of Medicinal Chemistry·Peter L ToogoodDavid W Fry
Jun 23, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Marcos Malumbres
Mar 4, 2011·Endocrine-related Cancer·Chellappagounder ThangavelErik S Knudsen
Nov 16, 2011·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Tim HuntBéla Novák
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Mar 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cynthia X MaMatthew J Ellis
May 24, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maura N DicklerJosé Baselga
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Aug 17, 2017·Nature·Shom GoelJean J Zhao
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Dec 14, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R CondorelliA Bardia
Jun 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis J SlamonGuy Jerusalem
Oct 23, 2018·The New England Journal of Medicine·Nicholas C TurnerMassimo Cristofanilli

❮ Previous
Next ❯

Citations

May 7, 2020·Clinical Chemistry and Laboratory Medicine : CCLM·Michael Vogeser
Sep 3, 2020·Endocrinology·Jessica Costa-GudaAndrew Arnold
Dec 11, 2019·Current Treatment Options in Cardiovascular Medicine·Avinash V SharmaAna Barac
Jun 18, 2020·International Journal of Molecular Sciences·Divya BafnaArtem Cherkasov
Apr 8, 2020·Breast Cancer : Targets and Therapy·Monica IorfidaElisabetta Munzone
Sep 19, 2020·Expert Opinion on Therapeutic Patents·Peng-Fei WangHai-Liang Zhu
Sep 10, 2020·International Journal of Molecular Sciences·Michela PiezzoMichelino De Laurentiis
Sep 1, 2019·Cellular and Molecular Life Sciences : CMLS·Jin ZhangZhengmao Zhu
Sep 15, 2020·Current Opinion in Oncology·José Pérez-GarcíaJavier Cortés
Nov 3, 2020·Asia-Pacific Journal of Clinical Oncology·Richard de BoerNicholas Zdenkowski
Nov 11, 2020·International Journal of Clinical Pharmacy·M García-Trevijano CabetasA Herrero Ambrosio
Dec 24, 2020·International Journal of Environmental Research and Public Health·Antonia MarcianòGiacomo Oteri
Nov 19, 2020·Breast Cancer : Targets and Therapy·Andrea Luque-BolivarMilena Rondón-Lagos
Dec 18, 2020·Frontiers in Chemistry·Bijay SinghSrinivas Sridhar
Jan 29, 2020·Seminars in Cancer Biology·Nikita PozdeyevRebecca E Schweppe
Jun 18, 2020·Seminars in Oncology·Elaine M WalshVered Stearns
Apr 7, 2021·Drug Metabolism Reviews·Laura E RussellVolker M Lauschke
Aug 3, 2021·Expert Review of Anticancer Therapy·Marcelle GoldnerNoam Pondé
Aug 28, 2021·Biomedicines·Morena FasanoRaffaele Solla
Nov 10, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Taylor DennisonAimee Faso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.